Clinical Trials Browser

OTHER × alectinib × 1 year × Clear all

NCT06354387 2026-03-19

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT05987644 2026-03-09

DURABLE

Phase 1/2 Recruiting

Brain Neoplasms, Lung Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04116541 2025-11-21

MegaMOST

Phase 2 Recruiting

Neoplasm Metastasis

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07001384 2025-08-14

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

Lymphoma, Large-Cell, Anaplastic

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT02314481 2025-05-23

DARWINII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT05713006 2025-05-01

Alectinib Pharmacokinetic in Patients With NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung